Brand Name :
Fotivda
Synonyms :
tivozanib
Class :
VEGF Inhibitor, Antineoplastics
Dosage forms & Strengths
Capsule
0.89mg
1.34mg
Indicated for Renal Cell Carcinoma
Take 1.34 mg orally once a day on Days 1-21 of each 28-day cycle
In case dose adjustments are necessary due to adverse reactions, lower the dose to 0.89 mg orally once per day for 21 days, after that followed by 7 days off the treatment
The safety and efficacy had not been established.
Refer to adult dosing.
may increase the QTc prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of each other when combined
may reduce the levels of serum concentration of tivozanib
may reduce the levels of serum concentration of tivozanib
may reduce the levels of serum concentration of tivozanib
may reduce the levels of serum concentration of tivozanib
may reduce the levels of serum concentration of tivozanib
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
It may enhance the risk of adverse effects when combined with Fluoroquinolones
It may enhance the risk of adverse effects when combined with Fluoroquinolones
It may enhance the risk of adverse effects when combined with Fluoroquinolones
It may enhance the risk of adverse effects when combined with Fluoroquinolones
It may enhance the risk of adverse effects when combined with Fluoroquinolones
may increase the arrhythmogenic effect of Inhalational Anaesthetics
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
It may diminish the metabolism when combined with Melatonin
It may diminish the metabolism when combined with Melatonin
It may diminish the metabolism when combined with Melatonin
It may diminish the metabolism when combined with Melatonin
Actions and Spectrum:
tivozanib is a tyrosine kinase inhibitor (TKI) that works by selectively blocking the activity of vascular endothelial growth factor (VEGF) receptors, which are proteins required in growth and survival of cancer cells. By inhibiting these receptors, tivozanib can slow down or stop the growth of tumors.
Specifically, tivozanib selectively targets and inhibits the VEGF receptors 1, 2, and 3, which are overexpressed in many types of cancer, including renal cell carcinoma (RCC). This inhibition reduces the blood supply to the tumor, which can slow down its growth and potentially lead to its regression.
tivozanib has a relatively narrow spectrum of activity compared to other TKIs, meaning it mainly targets VEGF receptors and has little effect on other tyrosine kinases. This selectivity is thought to contribute to its efficacy and safety profile. It has been shown to have a higher binding affinity for VEGF receptors compared to other TKIs, which may explain its improved clinical outcomes in patients with advanced RCC.
Frequency defined
>10%
1-10%
Black Box Warning:
Contraindication/Caution:
Contraindication
Caution
Pregnancy consideration:
US FDA pregnancy category: Not assigned
Lactation:
Excreted into human milk is Not known.
Pregnancy category:
Pharmacology:
Pharmacodynamics:
Pharmacokinetics:
Absorption
The maximum plasma concentration reached for this substance is 86.9 ng/mL 10 hours after administration, and the area under the concentration-time curve (AUC) is 1510 ng⋅hr/mL.
Distribution
The protein binding of this substance is equal to or greater than 99%, with a volume of distribution of 123 liters, and the mean ratios of blood-to-plasma concentrations range from 0.495 to 0.615 in healthy individuals.
Metabolism
CYP3A4 is the primary enzyme responsible for metabolizing it.
Elimination and Excretion
The half-life of this substance is 111 hours, and its clearance rate is 0.75 L/hr.
When a single 1.34-mg dose is administered, approximately 79% of the substance is excreted through faeces (with 26% being unchanged), while approximately 12% is excreted through urine (with no unchanged substance being detected).
Administration:
Oral Administration
Patient information leaflet
Generic Name: tivozanib
Pronounced: tivozanib [ tye-VOE-zan-ib ]
Why do we use tivozanib?
tivozanib is a medication used for the treatment of advanced renal cell carcinoma (RCC), which is a type of kidney cancer. It works by inhibiting the growth of new blood vessels that supply tumors, which can help to slow or stop the progression of cancer cells.
tivozanib is classified as a tyrosine kinase inhibitor and is specifically designed to target vascular endothelial growth factor (VEGF) receptors, which are inculpated in generation of new blood vessels in tumors.